Contract analysis

I. Executive Summary This memorandum is an internal post-mortem analysis summarizing the completed initial public offering of common stock of Arbor Health Technologies Inc. ("AHT" or the "Company"). It is prepared for the firm's institutional knowledge base and is intended to serve as a reference resource for future engagements involving healthcare SaaS and healthcare services company initial public offerings. The me

II. Transaction Overview A. Parties and Roles Issuer. Arbor Health Technologies Inc. is a Delaware C-corporation (EIN 47-3891205) founded in 2014 by Dr. Nathaniel Rourke and Margaret Tsujimoto. The Company operates a cloud-based clinical decision support and population health management platform serving over 1,200 hospital systems and physician groups across 42 states. In addition to its core SaaS platform, AHT provi

1. Repayment of Indebtedness. Approximately $65,000,000 to repay the outstanding balance on the Keypoint National Bank revolving credit facility, which bore interest at SOFR plus 200 basis points. The credit facility will remain in place following such repayment, providing the Company with continued access to the revolving commitment for working capital and other general corporate purposes.

2. Product Development and R&D Investment. Approximately $120,000,000 to fund investment in product development and research and development, including enhancement of the Company's clinical decision support platform, expansion of its population health management capabilities, and development of new real-time analytics modules.

3. Potential Acquisitions and Strategic Investments. Approximately $100,000,000 to fund potential acquisitions of, or strategic investments in, complementary businesses, technologies, and product offerings. While the Company did not have any specific acquisitions or investments identified at the time of the offering, management has indicated that the Company continually evaluates opportunities in the healthcare servi

4. General Corporate Purposes and Working Capital. The balance of net proceeds was designated for general corporate purposes and working capital needs, providing the Company with financial flexibility as it scales its operations.

III. Timeline and Key Milestones The following chronological summary reflects the key milestones of the engagement from inception through final closing of the overallotment: Elapsed Time Summary. Total elapsed time from engagement opening (August 21, 2023) to base closing (February 13, 2024) was approximately five months and twenty-three days. The period from confidential submission (November 10, 2023) to effectivene

IV. SEC Comment Letter Process and Themes A. Overview The Registration Statement was subject to two rounds of review and comment by the staff of the Division of Corporation Finance of the Securities and Exchange Commission. Round 1 consisted of 38 comments received on December 8, 2023, to which the working group submitted a comprehensive response and amended draft S-1 on December 22, 2023, achieving a 14-day turnarou

1. Non-GAAP Measures. The SEC Staff is increasingly focused on non-GAAP financial measures for SaaS and healthcare services companies. For future engagements, the firm should prepare detailed reconciliation tables and conduct a prominence analysis early in the S-1 drafting process to avoid time-consuming revisions during the comment period. 2. "Cheap Stock" Analysis. The "cheap stock" analysis for pre-IPO equity gran

3. Cybersecurity Disclosures. The new SEC cybersecurity disclosure rules require early attention for healthcare companies that process protected health information. The firm should build governance and risk factor disclosures addressing cybersecurity from the first draft of the Registration Statement to minimize comment exposure.

4. Comment Process Efficiency. The two-round comment process with a total of 49 comments was within the normal range for healthcare SaaS IPOs. The 14-day turnaround on Round 1 and the 7-day turnaround on Round 2 were critical to achieving the target public filing date of January 22, 2024, and maintaining the roadshow and pricing timeline. Rapid turnaround requires pre-positioned working group resources and daily coor

V. Pricing Dynamics and Range Revision A. Original Price Range and Market Context The initial Registration Statement filed publicly on January 22, 2024, included an estimated price range of $17.00 to $19.00 per share, with a midpoint of $18.00 per share. This range was established through a collaborative process involving the Company's management team, the lead left bookrunner (Whitfield Barrow), and the joint bookru

VI. Underwriting Agreement Negotiation A. Process The Underwriting Agreement was negotiated between C&H (on behalf of the Company) and Meridian Hale & Quivorn LLP (on behalf of the underwriters, with Whitfield Barrow & Co., LLC acting as the Representative of the several underwriters). The negotiation process proceeded as follows: Whitfield Barrow circulated the initial draft Underwriting Agreement through Meridian H

1. Whitfield Barrow's initial draft Underwriting Agreement contained an indemnification scope that was broader than prevailing market practice, particularly with respect to the Company's indemnification of the underwriters. Early identification of this issue and principled pushback by C&H were effective in achieving appropriate market-standard terms. The firm should maintain awareness of evolving underwriter drafting

2. The firm should maintain and regularly update its precedent database of underwriting agreement markups for healthcare SaaS IPOs. This database served as an invaluable resource during the AHT negotiation and should be expanded to include the AHT terms.

3. The scope of the market-out clause continues to evolve in response to macro-economic conditions and geopolitical developments. The firm should track market developments in this area, as underwriters may seek to expand termination trigger events in periods of elevated market volatility.

VII. Lock-Up Structure A. Terms The lock-up structure for the AHT IPO consisted of standalone lock-up agreements executed in favor of Whitfield Barrow & Co., LLC, as Representative of the several underwriters. The lock-up period was 180 days from the date of the final prospectus, February 8, 2024, resulting in a lock-up expiration date of August 6, 2024. Approximately 45 signatories executed lock-up agreements. The s

1. Estate Planning Transfers. Transfers to immediate family members, trusts for the benefit of immediate family members, and other transfers for estate planning purposes, provided that the donees or transferees execute a lock-up agreement substantially identical in form to the original lock-up agreement.

2. Pre-Existing Rule 10b5-1 Plans. Sales pursuant to pre-existing trading plans established in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, to the extent such plans were disclosed in the Registration Statement. A side letter was obtained from Whitfield Barrow confirming the specific parameters for existing plans maintained by Dr. Nathaniel Rourke and Margaret Tsujimoto, including the maximum

3. Open Market Acquisitions. The lock-up did not apply to shares of common stock acquired by the signatories in the open market after the IPO.

4. RSU Tax Withholding. Signatories were permitted to sell or surrender up to 10% of their locked-up shares in connection with tax withholding obligations arising from the vesting of restricted stock units during the lock-up period. C. Execution and Tracking Lock-up execution was tracked by Claire Dempsey using a spreadsheet-based tracker that identified each required signatory, tracked the delivery and execution sta

VIII. Overallotment Option The Underwriting Agreement granted the underwriters an option to purchase up to 3,000,000 additional shares of common stock (representing 15% of the base offering of 20,000,000 shares) at the public offering price of $20.00 per share, less the underwriting discount of $1.20 per share, for a net purchase price of $18.80 per share. The option was exercisable for 30 days following the date of

IX. Corporate Governance and Charter Documents Amended and Restated Certificate of Incorporation. The Company's Amended and Restated Certificate of Incorporation was filed with the Secretary of State of the State of Delaware on February 13, 2024, concurrent with the closing of the base offering. The A&R Certificate authorizes 400,000,000 shares of common stock, par value $0.001 per share, and 50,000,000 shares of pre

X. Equity Compensation Plans 2014 Stock Incentive Plan. The Company's 2014 Stock Incentive Plan (the "2014 Plan") was adopted at the time of the Company's founding and authorized the issuance of up to 12,000,000 shares of common stock. As of the IPO, 11,200,000 shares had been granted under the 2014 Plan in the form of stock options, of which 8,400,000 were vested. The weighted average exercise price of outstanding o

Section 83(b) Elections. A total of 14 current employees received restricted stock grants under the 2014 Plan during the period from 2021 to 2022. Each of these employees was eligible to file an election under Section 83(b) of the Internal Revenue Code to include the value of the restricted stock in income at the time of grant rather than at the time of vesting. Sylvia Hartwell confirmed that the compliance status of

XI. Stockholder Agreements — Termination and Survival Amended and Restated Investors' Rights Agreement. The Amended and Restated Investors' Rights Agreement, dated October 22, 2020, among the Company, Brindoval Trelvon Partners Fund IV, L.P., Ridgeline Growth Equity Fund III, LLC, and the founders, terminated by its terms upon the consummation of a "Qualified IPO," defined as an initial public offering generating gro

XII. Credit Facility Amendment and Payoff Keypoint Credit Facility. The Company maintains a $150,000,000 senior secured revolving credit facility entered into on March 15, 2022. The administrative agent is Keypoint National Bank, N.A. (200 Public Square, Cleveland, Ohio 44114), and Stonemill Capital Bank (140 Broadway, New York, New York 10005) participates as a syndicate member. The credit facility matures on March

XIII. D&O Insurance Program In connection with the IPO, the Company procured a directors and officers liability insurance program with a total tower of $100,000,000 in coverage. The program is structured in three layers: Primary Layer. Northbridge Specialty Insurance Company provides $50,000,000 per occurrence and in the aggregate, on a claims-made basis, with Side A (non-indemnifiable loss), Side B (corporate reimbu